Omeros has been granted a patent for a method to inhibit MASP-2-dependent complement activation in living subjects. The invention involves administering a MASP-2 inhibitory agent to prevent cellular injury while preserving the classical immune pathway. Additionally, compositions for inhibiting lectin-dependent complement activation are provided. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Omeros Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Omeros, Peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Method of inhibiting adverse effects of liver transplantation

Source: United States Patent and Trademark Office (USPTO). Credit: Omeros Corp

A recently granted patent (Publication Number: US11884742B2) discloses a method for inhibiting adverse effects of transplantation in subjects undergoing liver transplant procedures. The method involves administering a composition containing a monoclonal MASP-2 inhibitory antibody or its antigen-binding fragment, specifically binding to a portion of SEQ ID NO:6 to inhibit MASP 2 dependent complement activation. This approach aims to prevent or reduce inflammatory reactions resulting from organ transplantation, particularly liver transplants, by selectively inhibiting MASP-2 dependent complement activation while keeping C1q-dependent classical complement pathway activation intact.

Furthermore, the patent claims cover various aspects of the method, including the affinity of the antibody to SEQ ID NO:6, the administration routes (intra-arterial, intravenous, intramuscular, or subcutaneous), and the timing of administration (prior to, during, or post-transplantation). The method also extends to pretreating the organ to be transplanted with the composition, emphasizing the importance of selectively inhibiting MASP 2 dependent complement activation without substantially affecting C1q-dependent complement activation. This patent provides a novel approach to improving the outcomes of organ transplantation procedures, particularly liver transplants, by targeting specific complement activation pathways to mitigate adverse effects and enhance the overall success of the transplant process.

To know more about GlobalData’s detailed insights on Omeros, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies